The strong buying from high-conviction investors like RenTech and sovereign wealth fund Norges Bank, combined with Fidelity's aggressive doubling, suggests growing optimism about MRNA's post-pandemic pipeline or valuation reset. Traders should monitor upcoming clinical trial updates or partnerships as potential catalysts.
Executive Summary
Three major institutions — Fidelity, Norges Bank, and RenTech — significantly increased or initiated positions in Moderna (MRNA) during 2025-Q4, collectively adding over $605M in net new exposure. This buying was partially offset by a modest trim from BofA, which reduced its stake by $17.7M. The cluster suggests growing institutional confidence in MRNA despite recent underperformance.
Key Financial Metrics
Institutional Positions
Net institutional flow: $865.2M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Fidelity | DOUBLED | +127.9% | $827.1M | $509.2M |
| Norges Bank | NEW | +0% | $79.7M | $79.7M |
| RenTech | NEW | +0% | $16.8M | $16.8M |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| BofA | TRIM | -39.1% | $58.3M | -$17.7M |
Key Facts
- Fidelity doubled down on MRNA, increasing its position by 127.9% (15.74M shares) with a $509.2M value increase.
- Norges Bank and RenTech initiated new positions worth $79.7M and $16.8M, respectively.
- BofA trimmed its stake by 39.1%, reducing holdings by $17.7M.
- Net institutional flow: +$588M after accounting for all buyers and sellers.
Financial Impact
3 institutions accumulated $605.7M in net new positions while 1 reduced holdings by $17.7M, resulting in a net positive flow of $588M.
Risk Factors
- MRNA remains sensitive to vaccine demand and trial outcomes; any negative data could reverse sentiment.
- BofA's partial exit may reflect ongoing skepticism about long-term revenue sustainability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-MRNA-2025-Q4 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 2d ago | ANALYST-DOWNGRADE | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | ANALYST-DOWNGRADE | $148.87 $143.97 | ▲ +3.29% | ▲ +2.14% | — |
Aug 31, 2026 4w ago | Court Ruling | $140.19 $140.33 | ▼ −0.10% | ▼ −0.24% | — |
Aug 25, 2026 5w ago | ANALYST-UPGRADE | $158.83 $154.27 | ▼ −2.87% | ▼ −2.33% | — |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $174.38 $149.66 | ▼ −14.18% | ▼ −13.79% | — |
Aug 5, 2026 8w ago | 144 | $56.26 $63.67 | ▼ −13.18% | ▼ −12.83% | — |
Jul 31, 2026 9w ago | 8-K | $54.82 $59.17 | ▲ +7.94% | ▲ +4.42% | — |
Jul 10, 2026 11w ago | 3 | $67.01 $61.82 | ▼ −7.75% | ▼ −6.96% | — |
Jul 8, 2026 12w ago | 8-K | $73.80 $67.44 | ▼ −8.62% | ▼ −9.48% | — |
Jun 18, 2026 15w ago | 144 | $63.96 $59.75 | ▼ −6.58% | ▼ −4.92% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access